Schiess N, Cataldi R, Okun MS, Fothergill-Misbah N, Dorsey ER, Bloem BR, et al. Six action steps to address global disparities in Parkinson disease: a World Health Organization priority. JAMA Neurol. 2022;79(9):929–36.

Article  PubMed  Google Scholar 

Thompson A, Parekh A. Value of data sharing to advance drug development: a regulatory perspective. Ther Innov Regul Sci. 2021;55(4):850–2.

Article  PubMed  Google Scholar 

Maxfield KE, Buckman-Garner S, Parekh A. The role of public–private partnerships in catalyzing the critical path. Clin Transl Sci. 2017;10(6):431–42.

Article  PubMed  PubMed Central  Google Scholar 

Goldman M. Public-private partnerships need honest brokering. Nat Med. 2012;18(3):341–341.

Article  CAS  PubMed  Google Scholar 

Hendrikse NM, Llinares Garcia J, Vetter T, Humphreys AJ, Ehmann F. Biomarkers in medicines development—from discovery to regulatory qualification and beyond. Front Med. 2022 [cited 2023 Apr 3];9. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2022.878942

Chalasani M, Vaidya P, Mullin T. Enhancing the incorporation of the patient’s voice in drug development and evaluation. Res Involv Engagem. 2018;4(1):10.

Article  PubMed  PubMed Central  Google Scholar 

Saesen R, Lejeune S, Quaglio G, Lacombe D, Huys I. Views of European drug development stakeholders on treatment optimization and its potential for use in decision-making. Front Pharmacol. 2020;11:43.

Article  PubMed  PubMed Central  Google Scholar 

Concato J, Corrigan Curay J. Real-world evidence — where are we now? | NEJM [Internet]. [cited 2023 Apr 25]. Available from: https://www.nejm.org/doi.org/10.1056/NEJMp2200089

Li RJ, Ma L, Li F, Li L, Bi Y, Yuan Y, et al. Model-informed approach supporting drug development and regulatory evaluation for rare diseases. J Clin Pharmacol. 2022;62(S2):S27-37.

Article  CAS  PubMed  Google Scholar 

Karpen SR, White JK, Mullin AP, O’Doherty I, Hudson LD, Romero K, et al. Effective data sharing as a conduit for advancing medical product development. Ther Innov Regul Sci. 2021;55(3):591–600.

Article  PubMed  PubMed Central  Google Scholar 

Masanneck L, Gieseler P, Gordon WJ, Meuth SG, Stern AD. Evidence from ClinicalTrials.gov on the growth of digital health technologies in neurology trials. NPJ Digit Med. 2023;6(1):23.

Stephenson D, Alexander R, Aggarwal V, Badawy R, Bain L, Bhatnagar R, et al. Precompetitive consensus building to facilitate the use of digital health technologies to support Parkinson disease drug development through regulatory science. Digit Biomark. 2020;4(Suppl 1):28–49.

Article  PubMed  PubMed Central  Google Scholar 

Stephenson D, Badawy R, Mathur S, Tome M, Rochester L. Digital progression biomarkers as novel endpoints in clinical trials: a multistakeholder perspective. J Parkinsons Dis. 2021 Feb 11.

Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, et al. A biological classification of Huntington’s disease: the integrated staging system. Lancet Neurol. 2022;21(7):632–44.

Article  PubMed  Google Scholar 

Zhu H, Mehta M, Huang SM, Wang Y. Toward bridging unmet medical need in early Alzheimer’s disease: an evaluation of beta-amyloid (Aβ) plaque burden as a potential drug development tool. Clin Pharmacol Ther. 2022;111(4):728–31.

Article  PubMed  Google Scholar 

Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.

Article  PubMed  PubMed Central  Google Scholar 

Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, et al. Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities. Lancet Neurol. 2022;21(7):645–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kinnunen KM, Schwarz AJ, Turner EC, Pustina D, Gantman EC, Gordon MF, et al. Volumetric MRI-based biomarkers in Huntington’s disease: an evidentiary review. Front Neurol. 2021;12: 712555.

Article  PubMed  PubMed Central  Google Scholar 

Shefner JM, Bedlack R, Andrews JA, Berry JD, Bowser R, Brown R, et al. Amyotrophic lateral sclerosis clinical trials and interpretation of functional end points and fluid biomarkers: a review. JAMA Neurol. 2022;79(12):1312–8.

Article  PubMed  Google Scholar 

Manley GT, Mac Donald CL, Markowitz AJ, Stephenson D, Robbins A, Gardner RC, et al. The traumatic brain injury endpoints development (TED) initiative: progress on a public-private regulatory collaboration to accelerate diagnosis and treatment of traumatic brain injury. J Neurotrauma. 2017;34(19):2721–30.

Article  PubMed  PubMed Central  Google Scholar 

Kapoor R, Smith KE, Allegretta M, Arnold DL, Carroll W, Comabella M, et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology. 2020;95(10):436–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Veitch DP, Weiner MW, Aisen PS, Beckett LA, DeCarli C, Green RC, et al. Using the Alzheimer’s disease neuroimaging initiative to improve early detection, diagnosis, and treatment of Alzheimer’s disease. Alzheimer’s & Dementia. 2022;18(4):824–57.

Article  Google Scholar 

Tripathi SM, Murray AD. Alzheimer’s dementia: the emerging role of positron emission tomography. Neuroscientist. 2022;28(5):507–19.

Article  CAS  PubMed  Google Scholar 

Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, et al. Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nat Med. 2021;27(5):871–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kinnunen KM, Mullin AP, Pustina D, Turner EC, Burton J, Gordon MF, et al. Recommendations to optimize the use of volumetric MRI in Huntington’s disease clinical trials. Front Neurol. 2021;12: 712565.

Article  PubMed  PubMed Central  Google Scholar 

Hill DLG, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, et al. Coalition against major diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer’s disease. Alzheimer’s & Dementia. 2014;10(4):421-429.e3.

Article  Google Scholar 

Kalra S. Magnetic resonance spectroscopy in ALS. Front Neurol. 2019;10:482.

Article  PubMed  PubMed Central  Google Scholar 

Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR, et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Ann Neurol. 2016;79(4):535–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim S, Willcocks RJ, Daniels MJ, Morales JF, Yoon DY, Triplett WT, et al. Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials. CPT: Pharmacomet Syst Pharmacol. [cited 2023 Aug 29];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/psp4.13021

Romero K, Ito K, Rogers JA, Polhamus D, Qiu R, Stephenson D, et al. The future is now: model-based clinical trial design for Alzheimer’s disease. Clin Pharmacol Ther. 2015;97(3):210–4.

Article  CAS  PubMed  Google Scholar 

Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA. 2011;306(23):2608–9.

Article  CAS  PubMed  Google Scholar 

Bronson A, Chase MK, Fisher K, Millar D, Perlmutter J, Richardson N. Mobilizing the clinical trial ecosystem to drive adoption of master protocols. Clin Trials. 2022;19(6):690–6.

Article  PubMed  PubMed Central  Google Scholar 

Zeissler ML, Li V, Parmar MKB, Carroll CB. Is it possible to conduct a multi-arm multi-stage platform trial in Parkinson’s disease: lessons learned from other neurodegenerative disorders and cancer. J Parkinsons Dis. 2020;10(2):413–28.

Article  PubMed  PubMed Central  Google Scholar 

Federal Register, Department of Health and Human Services, 85 FR 25642. https://www.federalregister.gov/d/2020-07419